Trump Administration Urges Dismissal of Abortion Pill Lawsuit, Aligns with FDA Defense

[Social Media]

 

Trump Administration Urges Dismissal of Abortion Pill Lawsuit, Aligns with FDA Defense

 

In a significant legal move, the Trump administration has called for the dismissal of a high-profile lawsuit targeting the abortion pill mifepristone, aligning itself with the Biden-era Department of Justice in defending the authority of the Food and Drug Administration. In a court filing submitted on Monday, the DOJ argued that the case brought forward by three states—Idaho, Missouri, and Kansas—should not proceed in the Northern District of Texas, emphasizing that the states have no substantial connection to the venue where the original lawsuit was filed.

 

“Aside from this litigation, the States do not dispute that their claims have no connection to the Northern District of Texas,” the DOJ stated. “The states cannot keep alive a lawsuit in which the original plaintiffs were held to lack standing, those plaintiffs have now voluntarily dismissed their claims, and the States’ own claims have no connection to this District.”

 

The legal origins of the case trace back to 2022, when a coalition of anti-abortion physicians and medical groups initially challenged the FDA’s approval and regulation of mifepristone. However, the U.S. Supreme Court ultimately rejected that lawsuit, ruling that the plaintiffs failed to demonstrate personal harm resulting from the FDA’s actions. Without a direct injury, the justices determined that the conservative doctors lacked the legal standing required to bring the case forward.

 

Rather than filing a separate complaint, the three Republican-led states were permitted to intervene in the existing lawsuit, essentially stepping into the shoes of the dismissed plaintiffs. But now, with the Supreme Court having ruled against the original case and the DOJ asserting that the intervening states have no legitimate jurisdictional claim in Texas, the case’s future appears increasingly uncertain.

 

The issue of abortion access—particularly in relation to medication like mifepristone—has remained politically charged in the wake of the Supreme Court’s 2022 decision to overturn Roe v. Wade. Despite mounting pressure from anti-abortion advocates, former President Donald Trump has taken a relatively moderate stance on abortion pills during his 2024 campaign, repeatedly stating that he would not impose federal restrictions on their availability. He has insisted that abortion policies, including access to medication, should be determined by individual states rather than the federal government.

 

This position has disappointed and angered many anti-abortion groups that had strongly supported Trump’s reelection bid, and who continue to campaign for a national ban or tighter federal controls on mifepristone. The drug, which is used in combination with another medication to terminate pregnancies during the first 10 weeks, accounts for roughly two-thirds of all abortions in the United States.

 

While the Trump administration’s legal position in this case does not necessarily mark a broader policy shift, it underscores the complexity of the ongoing legal battles over reproductive rights and the tension between federal regulatory authority and state-led challenges. With the states’ claims now under renewed scrutiny and the lawsuit’s foundation weakened, the path forward for opponents of mifepristone appears increasingly narrow.

 

  Adpated by ASEAN Now from The Hill  2025-05-07